Skip to main content
. 2009 Mar 4;101(5):341–349. doi: 10.1093/jnci/djn498

Figure 2.

Figure 2

Survival and disease outcomes according to goserelin treatment. A) The percentages (95% confidence interval [CI]) of women treated with goserelin who experienced death, had recurrence, or had a new tumor at 5, 10, and 15 years were 25 (23 to 27), 38 (35 to 41), and 47 (43 to 51), respectively; corresponding percentages in control women were 32 (29 to 35), 43 (40 to 46), and 52 (48 to 55). B) The percentages (95% CI) of women treated with goserelin who died at 5, 10, and 15 years were 12 (10 to 14), 21 (19 to 23), and 29 (26 to 32), respectively; the corresponding percentages in control women were 15 (13 to 17), 26 (23 to 28), and 33 (30 to 36). C) The percentages (95% CI) of women treated with goserelin who had a recurrence at 5, 10, and 15 years were 22 (20 to 24), 31 (28 to 34), and 36 (33 to 39), respectively; the corresponding percentages in control women were 27 (24 to 29), 37 (34 to 40), and 42 (39 to 45). D) The percentages (95% CI) of women treated with goserelin who died from breast cancer at 5, 10, and 15 years were 11 (9 to 13), 20 (18 to 22), and 26 (23 to 29), respectively; the corresponding percentages in control women were 14 (12 to 16), 24 (22 to 26), and 30 (27 to 33). Two-sided P values from log-rank tests are shown.